Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders

Details

Ressource 1Download: 31548534_BIB_7291979F12C3.pdf (479.84 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_7291979F12C3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders
Journal
Antibodies (Basel)
Author(s)
Vanhove B., Poirier N., Fakhouri F., Laurent L., t Hart B., Papotto P. H., Rizzo L. V., Zaitsu M., Issa F., Wood K., Soulillou J. P., Blancho G.
ISSN
2073-4468 (Electronic)
ISSN-L
2073-4468
Publication state
Published
Issued date
2017
Volume
6
Number
4
Language
english
Notes
Vanhove, Bernard
Poirier, Nicolas
Fakhouri, Fadi
Laurent, Laetitia
't Hart, Bert
Papotto, Pedro H
Rizzo, Luiz V
Zaitsu, Masaaki
Issa, Fadi
Wood, Kathryn
Soulillou, Jean-Paul
Blancho, Gilles
eng
Review
Switzerland
Antibodies (Basel). 2017 Nov 21;6(4). pii: antib6040019. doi: 10.3390/antib6040019.
Abstract
The effector functions of T lymphocytes are responsible for most autoimmune disorders and act by directly damaging tissues or by indirectly promoting inflammation and antibody responses. Co-stimulatory and co-inhibitory T cell receptor molecules are the primary pharmacological targets that enable interference with immune-mediated diseases. Among these, selective CD28 antagonists have drawn special interest, since they tip the co-stimulation/co-inhibition balance towards efficiently inhibiting effector T cells while promoting suppression by pre-existing regulatory T-cells. After having demonstrated outstanding therapeutic efficacy in multiple models of autoimmunity, inflammation and transplantation, and safety in phase-I studies in humans, selective CD28 antagonists are currently in early clinical development for the treatment of systemic lupus erythematous and rheumatoid arthritis. Here, we review the available proof of concept studies for CD28 antagonists in autoimmunity, with a special focus on the mechanisms of action.
Keywords
T cell costimulation, antibodies, autoimmunity, N.P. are shareholders and employees of OSE Immunotherapeutics, a biotech company, developing CD28 antagonists. J.-P.S. is a shareholder of OSE Immunotherapeutics.
Pubmed
Create date
01/03/2022 11:18
Last modification date
23/11/2022 8:12
Usage data